Jared C. Foster

Also affiliated with National Cancer Institute

MedicineMathematicsEconomics, Econometrics and Finance

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 9 papers. Top paper: “Atezolizumab for Advanced Alveolar Soft Part Sarcoma”.

Atezolizumab for Advanced Alveolar Soft Part Sarcoma

New England Journal of Medicine(2023)10.1056/nejmoa2303383

N/A

3.3DataRank · unranked

158 citations

Elad Sharon, Geraldine O’Sullivan Coyne, Nancy Moore, Jared C. Foster, James Hu +26 more

Selumetinib in adults with NF1 and inoperable plexiform neurofibroma: a phase 2 trial

Nature Medicine(2025)10.1038/s41591-024-03361-4

N/A

0.954DataRank · unranked

41 citations

Geraldine O’Sullivan Coyne, Eva Dombi, Cecilia Tibery, William G. Herrick, Staci Martin +30 more

Trial Design Considerations to Increase Older Adult Accrual to National Cancer Institute Clinical Trials

JNCI Monographs(2022)10.1093/jncimonographs/lgac023

N/A

0DataRank · unranked

29 citations

Supriya G. Mohile, Joseph M. Unger, Matthew F. Hudson, Jared C. Foster, Stuart M. Lichtman +11 more

A phase 2 study of anti-PD-L1 antibody (atezolizumab) in grade 2 and 3 chondrosarcoma.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.11528

N/A

0DataRank · unranked

3 citations

Anthony P. Conley, James Lin Chen, Elizabeth J. Davis, Melissa Burgess, Albiruni Ryan Abdul Razak +13 more

A phase 2 study of an anti–PD-L1 antibody (atezolizumab) in dedifferentiated chondrosarcoma.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.11533

N/A

0DataRank · unranked

1 citations

Brian Ko, Brian A. Van Tine, Anthony P. Conley, Elizabeth J. Davis, Melissa Burgess +12 more

Phase 2 evaluation of the nilotinib-paclitaxel combination in patients with rare solid tumors: Rapid analysis and response evaluation of combination anti-neoplastic agents in rare tumors trial 1 (RARE CANCER 1).

Journal of Clinical Oncology(2025)10.1200/jco.2025.43.16_suppl.3015

N/A

0DataRank · unranked

0 citations

Andre DeSouza, Jared C. Foster, Naoko Takebe, Geraldine O’Sullivan Coyne, Sarah Miller +8 more

Molecular Profiling-Based Assignment of Cancer Therapy (NCI-MPACT): A Randomized Multicenter Phase II Trial

JCO Precision Oncology(2021)10.1200/po.20.00372

N/A

0DataRank · unranked

45 citations

Shivaani Kummar, Nancy Moore, Larry Rubinstein, Yingdong Zhao, P. Mickey Williams +20 more

Rapid analysis and response evaluation of combination anti-neoplastic agents in rare tumors (RARE CANCER) trial: RARE 2 talazoparib and temozolomide.

Journal of Clinical Oncology(2025)10.1200/jco.2025.43.16_suppl.3155

N/A

0DataRank · unranked

0 citations

Jennifer Zlott, Jared C. Foster, Sarah J. Shin, Geraldine O’Sullivan Coyne, Naoko Takebe +5 more

Phase II study of atezolizumab in advanced alveolar soft part sarcoma (ASPS).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.11519

N/A

0DataRank · unranked

50 citations

Geraldine O’Sullivan Coyne, Nancy Moore, Elad Sharon, Naoko Takebe, Kristin Fino +15 more